Karuna Therapeutics (Karuna Therapeutics) Long-Term Capital Lease Obligation : $13.85 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Karuna Therapeutics Long-Term Capital Lease Obligation?

Karuna Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.85 Mil.

Karuna Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($13.83 Mil) to Sep. 2023 ($13.81 Mil) but then increased from Sep. 2023 ($13.81 Mil) to Dec. 2023 ($13.85 Mil).

Karuna Therapeutics's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($5.33 Mil) to Dec. 2022 ($3.05 Mil) but then increased from Dec. 2022 ($3.05 Mil) to Dec. 2023 ($13.85 Mil).

Karuna Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Karuna Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karuna Therapeutics Long-Term Capital Lease Obligation Chart

Karuna Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.15

1.84

5.33

3.05

13.85

Karuna Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															3.05	2.69	13.83	13.81	13.85

Karuna Therapeutics (NAS:KRTX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Karuna Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Karuna Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Karuna Therapeutics (Karuna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karuna Therapeutics Inc (NAS:KRTX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

KRTX:Mexico

Address

99 High Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.karunatx.com

Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.

Executives

Stephen K. Brannan	officer: Chief Medical Officer	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jason Parker Brown	officer: Chief Financial Officer	KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Jeffrey M Jonas	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Troy A. Ignelzi	officer: Chief Financial Officer	C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Andrew Craig Miller	officer: Chief Operating Officer	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Laurie J Olson	director	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Kane William P Jr	officer: Chief Commercial Officer	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
William Meury	director, officer: President and CEO	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Charmaine Lykins	officer: Chief Commercial Officer	C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Steven M Paul	director, officer: President & CEO	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Puretech Health Llc	10 percent owner	501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045